Peer-reviewedCC BY 4.0Frontiers in Immunology
Editorial: The experimental models as a tool for studying therapeutic targets in COPD: lessons learned
7 affiliations
- 1Laboratory of Experimental Therapeutics (LIM20), Department of Clinical Medicine, School of Medicine, University of Sao Paulo
- 2Thoracic Surgery Research Laboratory (LIM61), Division of Thoracic Surgery, Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
- 3Evangelical University of Goias (UniEvangelica), Laboratory of Pulmonary and Exercise Immunology (LABPEI)
- 4Brazilian Institute of Teaching and Research in Pulmonary and Exercise Immunology (IBEPIPE), Department of Research and Development
- 5Respiratory Research Center, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- 6Division of Respiratory Critical Care Physiology and Medicine, Harbor-UCLA Medical Center
- 7College of Health Sciences, The University of Texas at El Paso
Related
- Editorial: Potential therapeutic targets in alcohol use disorder: insights from recent preclinical studies
- Studying the regulons of OmrA and OmrB paralogous small RNAs reveals targets involved in central carbon metabolism and lipogenesis
- Editorial: Immunometabolism at the intersection of signaling networks and therapeutic strategies
- Editorial: Inflammation and diabetes: unraveling vascular complications and therapeutic innovations
- A Human Precision Cut Kidney Slice Platform for Studying Glomerular Biology and Therapeutic Responses
BibTeX
@article{lopes2026editorial,
title = {{Editorial: The experimental models as a tool for studying therapeutic targets in COPD: lessons learned}},
author = {Fernanda Degobbi T Q S Lopes and Rodolfo P Vieira and Asghar Abbasi},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1988969},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1988969/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Editorial: The experimental models as a tool for studying therapeutic targets in COPD: lessons learned
AU - Fernanda Degobbi T Q S Lopes
AU - Rodolfo P Vieira
AU - Asghar Abbasi
PY - 2026
DA - 2026/10/01
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1988969
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1988969/full
SN - 1664-3224
ER -